Literature DB >> 16114280

Severe systemic complications of acromegaly.

A Colao1, R Pivonello, P Marzullo, R S Auriemma, M C De Martino, D Ferone, G Lombardi.   

Abstract

It is well accepted that mortality in acromegaly is increased because of cardiovascular and respiratory diseases while neoplastic complications account less to mortality. Amongst different cardiovascular complications the most frequent is biventricular hypertrophy, which occurs independently of hypertension and metabolic complications that, in turn, aggravate the cardiomyopathy. Diastolic and systolic dysfunction develops in a variable number of patients, depending on age and disease duration. Other cardiac disorders, such as arrhythmias, valve disease, hypertension, atherosclerosis and endothelial dysfunction have been less characterized but all appear to be present in acromegaly, depicting the so called "acromegalic cardiomyopathy". The best characterized respiratory disease is the sleep apnea. Ventilatory dysfunction recognizes bony changes of thoracic cage and lung overgrowth as relevant pathogenetic factors. Earlier evidences that patients with acromegaly have an increased risk of developing malignancies have become more realistic in recent years. Most studies have reported an increased risk of colonic polyps, which more frequently recur in patients not controlled after treatment. Malignancies in other organs have also been described, but less convincingly than at the gastrointestinal level and are not a main cause of mortality. Bone changes are also feature of the disease. They involve theoretically all bones and, particularly, the appendicular and the axial skeleton. Patients with long-standing disease are more prone to develop degenerative changes. Control of acromegaly by surgery or pharmacotherapy, especially by somatostatin analogs, improves cardiovascular morbidity and sleep apnea. There is still no demonstration that improvement of different complications corresponds a reduction in mortality.

Entities:  

Mesh:

Year:  2005        PMID: 16114280

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  6 in total

1.  Hand and foot abnormalities associated with genetic diseases.

Authors:  Henry J Mankin; Jesse Jupiter; Carol Ann Trahan
Journal:  Hand (N Y)       Date:  2010-10-26

2.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

3.  POTENTIAL NON-GROWTH USES OF rhIGF-I.

Authors:  Roy J Kim; Adda Grimberg
Journal:  Growth Genet Horm       Date:  2007-03

4.  Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.

Authors:  Brian J Potter; Catherine Beauregard; Omar Serri
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

5.  Growth hormone is permissive for neoplastic colon growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Cuiqi Zhou; Maria Victoria Recouvreux; Anat Ben-Shlomo; Takako Araki; Robert Barrett; Michael Workman; Kolja Wawrowsky; Vladimir A Ljubimov; Magdalena Uhart; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-25       Impact factor: 11.205

Review 6.  Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature.

Authors:  Sebastian Krug; Michael Boch; Peter Rexin; Andreas Pfestroff; Thomas Gress; Patrick Michl; Anja Rinke
Journal:  BMC Res Notes       Date:  2016-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.